12:00 AM
Mar 22, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Betrixaban: Phase IIb data

Data from the international, dose-finding Phase IIb EXPLORE-Xa trial in 508 patients showed that 40 mg once-daily betrixaban significantly reduced the incidence of major or clinically relevant non-major bleeding vs. open-label, dose-adjusted warfarin (0.8% vs. 5.5%, p=0.035). The incidence of major or clinically...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >